Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
NSPR 
InspireMD Inc (NSPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/10/2025: NSPR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.64% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 80.08M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 2 | Beta 0.69 | 52 Weeks Range 1.59 - 3.80 | Updated Date 12/10/2025 |
52 Weeks Range 1.59 - 3.80 | Updated Date 12/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -517.28% |
Management Effectiveness
Return on Assets (TTM) -45.46% | Return on Equity (TTM) -87.61% |
Valuation
Trailing PE - | Forward PE 11.7 | Enterprise Value 20051180 | Price to Sales(TTM) 10.29 |
Enterprise Value 20051180 | Price to Sales(TTM) 10.29 | ||
Enterprise Value to Revenue 2.14 | Enterprise Value to EBITDA 0.52 | Shares Outstanding 42370995 | Shares Floating 22871016 |
Shares Outstanding 42370995 | Shares Floating 22871016 | ||
Percent Insiders 17 | Percent Institutions 53.65 |
Upturn AI SWOT
InspireMD Inc
Company Overview
History and Background
InspireMD Inc. was founded in 2003, originally as an Israeli-based company focused on developing innovative vascular devices. A significant milestone was its transition to a U.S.-based entity and listing on the NYSE American exchange. The company has undergone several strategic shifts and product development cycles, aiming to address unmet needs in interventional cardiology and radiology.
Core Business Areas
- Interventional Cardiology & Radiology Devices: InspireMD focuses on developing and commercializing advanced medical devices, primarily for the treatment of cardiovascular and peripheral vascular diseases. Their core product line aims to improve patient outcomes in complex vascular interventions.
Leadership and Structure
InspireMD's leadership team typically comprises experienced professionals in the medical device industry, including a CEO, CFO, and heads of R&D, Sales, and Operations. The organizational structure is designed to support product development, regulatory affairs, clinical trials, manufacturing, and commercialization efforts.
Top Products and Market Share
Key Offerings
- MGuard Prime EPS: The MGuard Prime EPS is a drug-eluting stent system designed for the treatment of coronary artery disease. It features a porous, ePTFE-covered stent designed to provide protection against distal embolization. Its market share is influenced by competition from major stent manufacturers. Competitors include Abbott Laboratories (Xience), Boston Scientific (Prometheus), Medtronic (Resolute Integrity), and Johnson & Johnson (Pro-Kinetic Energy).
- CGuard EPS: The CGuard EPS is an embolic protection device designed to capture debris during interventional procedures, reducing the risk of stroke and other embolic events. It is positioned as a key offering for complex peripheral and coronary interventions. Competitors include manufacturers of distal protection devices like Boston Scientific (FilterWire EZ) and Medtronic (Emboshield).
Market Dynamics
Industry Overview
The medical device industry, particularly in the cardiovascular and interventional space, is highly competitive and innovation-driven. It is characterized by significant R&D investment, stringent regulatory pathways (FDA, CE Mark), and a focus on improving patient outcomes and procedural efficiency. Reimbursement policies also play a crucial role in market adoption.
Positioning
InspireMD positions itself as a developer of innovative solutions addressing specific unmet needs in vascular interventions, particularly focusing on embolic protection and advanced stenting. Its competitive advantage lies in its proprietary technologies aimed at enhancing safety and efficacy in complex procedures.
Total Addressable Market (TAM)
The global market for cardiovascular devices, including stents and embolic protection systems, is substantial, estimated to be in the tens of billions of dollars annually. InspireMD is positioned to capture a niche within this large TAM by focusing on differentiated products that offer distinct clinical benefits.
Upturn SWOT Analysis
Strengths
- Proprietary technologies in embolic protection and stenting.
- Focus on addressing unmet clinical needs in complex vascular procedures.
- Experienced management team with a track record in the medical device industry.
Weaknesses
- Relatively small market share compared to established giants.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Potential for limited financial resources for aggressive market expansion.
Opportunities
- Growing demand for minimally invasive cardiovascular procedures.
- Expansion into new geographic markets and indications.
- Partnerships or collaborations with larger medical device companies.
- Advancements in interventional techniques creating demand for novel devices.
Threats
- Intense competition from large, well-capitalized medical device manufacturers.
- Changes in reimbursement policies affecting device adoption.
- Stringent and evolving regulatory requirements.
- Potential for product obsolescence due to rapid technological advancements.
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- Boston Scientific Corporation (BSX)
- Medtronic plc (MDT)
Competitive Landscape
InspireMD faces a competitive landscape dominated by large, established medical device companies with significant R&D budgets, extensive sales forces, and strong brand recognition. InspireMD's advantages lie in its focus on niche technologies and its agility as a smaller player. However, it faces challenges in matching the scale of operations and market access of its larger competitors.
Growth Trajectory and Initiatives
Historical Growth: InspireMD's historical growth has been driven by product development, clinical trial progress, and market penetration efforts. This has been a period of focused investment and strategic positioning.
Future Projections: Future growth projections for InspireMD are contingent on the successful commercialization of its pipeline products, regulatory approvals, and market adoption. Analyst estimates, if available, would provide insights into expected future performance.
Recent Initiatives: Recent initiatives likely involve advancing clinical trials for key products like CGuard EPS, seeking regulatory approvals in major markets, and expanding sales and distribution networks to drive commercial uptake.
Summary
InspireMD Inc. operates in a competitive but large market for cardiovascular devices. Its strengths lie in its innovative product pipeline, particularly in embolic protection. However, the company faces challenges related to market penetration, competition from larger players, and the need for ongoing clinical and regulatory success. Strategic partnerships and successful commercialization of its differentiated offerings will be crucial for its future growth and profitability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC filings (10-K, 10-Q)
- Financial news and market data providers
- Industry analysis reports
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Market share data is an estimation based on industry trends and may not be precise. Future projections are speculative. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InspireMD Inc
Exchange NASDAQ | Headquaters Miami, FL, United States | ||
IPO Launch date 2011-04-12 | President, CEO & Director Mr. Marvin L. Slosman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 66 | Website https://www.inspiremd.com |
Full time employees 66 | Website https://www.inspiremd.com | ||
InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as well as treating acute stroke with tandem lesions. It has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Miami, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.